(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 151.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Renovorx's revenue in 2026 is $1,976,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $181,330,363, with the lowest RNXT revenue forecast at $166,888,921, and the highest RNXT revenue forecast at $191,574,761. On average, 6 Wall Street analysts forecast RNXT's revenue for 2027 to be $548,323,522, with the lowest RNXT revenue forecast at $442,269,178, and the highest RNXT revenue forecast at $663,945,322.
In 2028, RNXT is forecast to generate $1,534,448,402 in revenue, with the lowest revenue forecast at $1,037,030,964 and the highest revenue forecast at $2,247,900,793.